Skip to Content

How does Ilumya work to treat psoriasis?

Answers (1)

Official Answer by 19 Jun 2018

Psoriasis is an autoimmune skin condition that causes raised, itchy, red lesions and scales that can occur on the elbows, scalp, knees, and lower back.

In March, 2018 the FDA approved Ilumya (tildrakizumab-asmn), a humanized interleukin-23 p19 subunit antagonist (anti-IL-23p19) monoclonal antibody for moderate-to-severe plaque psoriasis in adults who are candidates for systemic treatment or phototherapy (ultraviolet or UV light).

The mechanism of psoriasis is thought to be due to activation of myeloid dendritic cells which release IL-23 and other cytokines to activate T cells (a type of white blood cell).

Ilumya is a human monoclonal antibody cytokine that works by targeting the p19 subunit of IL-23 to disrupt the inflammatory process involved in psoriasis. free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What disease is Elzonris (tagraxofusp-erzs) used to treat?

Updated 7 Jan 2019 1 answerFAQ by

How do you use the ProAir Digihaler?

Updated 7 Jan 2019 1 answerFAQ by

How many biosimilars have been approved in the United States?

Updated 8 Jan 2019 1 answerFAQ by

What are the brands of sumatriptan?

Updated 5 Feb 2019 1 answerFAQ by

What is botulinum toxin used to treat?

Updated 14 Feb 2019 1 answerFAQ by